---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-124510"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2023-04-28T23:59:59+00:00"
generated_at: "2026-06-16T06:25:37.556625+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tempest reports positive early Phase 1b/2 data for TPST-1120 in HCC; ORR improved vs control

## Summary
- Unconfirmed ORR 30% (12/40) for TPST-1120 arm vs 17.2% (5/29) control, a 74.4% relative improvement.
- Confirmed ORR 17.5% (7/40) vs 10.3% (3/29) control, a 69.9% relative improvement.
- 47.5% (19/40) of TPST-1120 arm patients remain on treatment vs 23.3% (7/30) in control arm.
- 80% (32/40) in TPST-1120 arm on study vs 50% (15/30) control; safety consistent with control.
- Secondary endpoints (DoR, PFS, OS) immature; full data expected at a medical meeting later.

## SEC filing metadata
- accession: 0001193125-23-124510
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2023-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312523124510/0001193125-23-124510-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312523124510/d479206d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-124510
- JSON: https://secwatch.observer/filing/0001193125-23-124510.json
- Plain text: https://secwatch.observer/filing/0001193125-23-124510.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.